BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28866695)

  • 1. The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting.
    Peiris H; Mudduwa L; Thalagala N; Jayatialake K
    Malays J Pathol; 2017 Aug; 39(2):141-148. PubMed ID: 28866695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka.
    Peiris H; Mudduwa L; Thalagala N; Jayatilake K
    BMC Womens Health; 2018 Jan; 18(1):30. PubMed ID: 29385991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer.
    Oshiro C; Yamasaki M; Noda Y; Nishimae A; Takahashi H; Inaji H
    Breast Cancer; 2020 Sep; 27(5):947-953. PubMed ID: 32297249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.
    Blancas I; García-Puche JL; Bermejo B; Hanrahan EO; Monteagudo C; Martínez-Agulló A; Rouzier R; Hennessy BT; Valero V; Lluch A
    Ann Oncol; 2006 Nov; 17(11):1644-9. PubMed ID: 16873428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer.
    Rose BS; Jiang W; Punglia RS
    Breast Cancer Res Treat; 2015 Jul; 152(1):209-216. PubMed ID: 26041688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
    J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferative epithelial changes in tumour adjacent tissue in Sri Lankan women with breast carcinoma: do morphological changes support molecular models of breast carcinogenesis?
    Jinadasa IM; Wijesinghe HD; Jayawickrama MMA; Lokuhetty MDS
    Diagn Pathol; 2022 Dec; 17(1):97. PubMed ID: 36581929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.
    Rakha EA; El-Sayed ME; Lee AH; Elston CW; Grainge MJ; Hodi Z; Blamey RW; Ellis IO
    J Clin Oncol; 2008 Jul; 26(19):3153-8. PubMed ID: 18490649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
    J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
    Chen HL; Zhou MQ; Tian W; Meng KX; He HF
    PLoS One; 2016; 11(10):e0165409. PubMed ID: 27798652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage.
    Rakha EA; Morgan D; Macmillan D
    J Clin Pathol; 2012 Jul; 65(7):624-30. PubMed ID: 22523340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
    Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival.
    Oven Ustaalioglu BB; Balvan O; Bilici A; Develi A; Aliustaoglu M; Vardar FA; Erkol B
    Clin Transl Oncol; 2015 Nov; 17(11):895-902. PubMed ID: 26081286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.